Table S1: The search strategy to identify the top 100 highest-cited original articles from WOSCC database.

Type	Search Query	Results
Search #1	TOPIC: (biologic therapy) OR TOPIC: (biological therapy) OR TOPIC: (biologic treatment) OR TOPIC: (biological treatment) OR TOPIC: (biologic agent) OR TOPIC: (biological agent) OR TOPIC: (biologic drugs) OR TOPIC: (biological drugs) OR TOPIC: (anti-tumor necrosis factor) OR TOPIC: (anti-TNF) OR TOPIC: (infliximab) OR TOPIC: (IFX) OR TOPIC: (adalimumab) OR TOPIC: (ADA) OR TOPIC: (certolizumab) OR TOPIC: (CZP) OR TOPIC: (anti-integrin) OR TOPIC: (vedolizumab) OR TOPIC: (VEDO) OR TOPIC: (natalizumab) OR TOPIC: (NAT) OR TOPIC: (anti-IL-12/23) OR TOPIC: (ustekinumab) OR TOPIC: (UST)	403,580
Search #2	TOPIC: (Crohn disease) OR TOPIC: (Crohn's disease)	49,706
Search #3	#1 AND #2 AND Document Types: (Articles)	5,489

Note:

Indexes= SCI-EXPANDED, CCR-EXPANDED.

Timespan= From January, 1991 to December, 2020.

WOSCC: Web of Science Core Collection.

Table S2: The top 100 highest-cited original articles in the biologic therapy of CD.

Rank	Article	TC
1	Hanauer SB, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet*. 2002;359:1541-1549.	2,978
2	Keane J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent. *New Engl J Med*. 2001;345:1098-1104.	2,649
3	Rutgeerts P, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *New Engl J Med*. 2005;353:2462-2476.	2,461
4	Present DH, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. *New Engl J Med*. 1999;340:1398-1405.	1,931
5	Colombel JF, et al. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. *New Engl J Med*. 2010;362:1383-1395.	1,923
6	Baert F, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *New Engl J Med*. 2003;348:601-608.	1,517
7	Colombel JF, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. *Gastroenterology*. 2007;132:52-65.	1,460
8	Sands BE, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. *New Engl J Med*. 2004;350:876-885.	1,436
9	Hanauer SB, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. *Gastroenterology*. 2006;130:323-332.	1,114
10	Sandborn WJ, et al. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. *New Engl J Med*. 2013;369:711-721.	1,054
11	Dignass A, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. *J Crohns Colitis*. 2010;4:28-62.	1,045
12	Vandullemen HM, et al. Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal-antibody (CA2). *Gastroenterology*. 1995;109:129-135.	926
13	Rutgeerts P, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. *Gastroenterology*. 1999;117:761-769.	873
14	Hueber W, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. *Gut*. 2012;61:1693-1700.	872
15	D'Haens G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open	863

randomised trial. *Lancet*. 2008;371:660-667.

16 Gomollon F, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. *J Crohns Colitis*. 2017;11:3-25. 835

17 Sandborn WJ, et al. Certolizumab pegol for the treatment of Crohn's disease. *New Engl J Med*. 2007;357:228-1238. 791

18 Schreiber S, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. *New Engl J Med*. 2007;357:239-250. 762

19 Van Assche G, et al. Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. *New Engl J Med*. 2005;353:362-368. 759

20 Froslie KF, et al. Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. *Gastroenterology*. 2007;133:412-422. 750

21 Colombel JF, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. *Gastroenterology*. 2004;126:19-31. 690

22 Beaugerie L, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet*. 2009;374:1617-1625. 686

23 Rutgeerts P, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. *Gastroenterology*. 2004;126:402-413. 685

24 Sandborn WJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. *Gut*. 2007;56:1232-1239. 681

25 Sandborn WJ, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial. *Ann Intern Med*. 2007;146:829-838. 668

26 Sandborn WJ, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. *Gastroenterology*. 2001;121:1088-1094. 663

27 Sandborn WJ, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. *New Engl J Med*. 2012;367:1519-1528. 656

28 Lichtenstein GR, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. *Clin Gastroenterol Hepatol*. 2006;4:621-630. 655

29 Sandborn WJ, et al. Natalizumab induction and maintenance therapy for Crohn's disease. *New Engl J Med*. 2005;353:1912-1925. 651

30 Suhre K, et al. Human metabolic individuality in biomedical and pharmaceutical research. *Nature*. 2011;477:54-60. 632
31 Feagan BG, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. *New Engl J Med*. 2016;375:1946-1960. 623
32 Parameswaran N, et al. Tumor necrosis factor-a signaling in macrophages. *Crit Rev Eukaryot Gene Expr*. 2010.20:87-103. 618
33 Ghosh S, et al. Natalizumab for active Crohn's disease. *New Engl J Med*. 2003;348:24-32. 616
34 Van Den Brande JMH, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. *Gastroenterology*. 2003;124:1774-1785. 575
35 Beaugerie L, et al. Predictors of Crohn's disease. *Gastroenterology*. 2006;130:650-656. 572
36 D'Haens G, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. *Gastroenterology*. 1999;116:1029-1034. 569
37 Baert F, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. *Gastroenterology*. 2010;138:463-468. 563
38 Hyams J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. *Gastroenterology*. 2007;132:863-873. 554
39 Yousry TA, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. *New Engl J Med*. 2006;354:924-933. 550
40 Sandborn WJ, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. *Gastroenterology*. 2008;135:1130-1141. 532
41 Ruemmele FM, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. *J Crohns Colitis*. 2014;8:1179-1207. 517
42 Scallon B, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. *J Pharmacol Exp Ther*. 2002;301:418-426. 514
43 Garcia-Olmo D, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a Phase II clinical trial. *Dis Colon Rectum*. 2009;52:79-86. 498
44 Cosnes J, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. *Gut*. 2005;54:237-241. 490
45 Hanauer SB, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. *Clin* 489

Gastroenterol Hepatol. 2004;2:542-553.

46 Lugering A, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. *Gastroenterology*. 2001;121:1145-1157. 486

47 Ramos-Casals M, et al. Autoimmune diseases induced by TNF-targeted therapies - Analysis of 233 cases. *Medicine*. 2007;86:242-251. 480

48 Vande Casteele N, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. *Gastroenterology*. 2015;148:1320-9.e3. 472

49 Braat H, et al. A phase I trial with Transgenic bacteria expressing interleukin-10 in Crohn's disease. *Clin Gastroenterol Hepatol*. 2006;4:754-759. 468

50 Ito H, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. *Gastroenterology*. 2004;126:989-996. 467

51 Brown SL, et al. Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration. *Arthritis Rheum*. 2002;46:3151-3158. 464

52 Zouboulis CC, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. *J Eur Acad Dermatol Venereol*. 2015;29:619-644. 463

53 Schnitzler F, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. *Inflamm Bowel Dis*. 2009;15:1295-1301. 462

54 Shishodia S, et al. Getting back to the roots. *Ann N Y Acad Sci*. 2005;1056:206-217. 461

55 Maser EA, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. *Clin Gastroenterol Hepatol*. 2006;4:1248-1254. 458

56 ten Hove T, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. *Gut*. 2002;50:206-211. 439

57 Targan SR, et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial. *Gastroenterology*. 2007;132:1672-1683. 435

58 Peyrin-Biroulet L, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. *Clin Gastroenterol Hepatol*. 2008;6:644-653. 434

59 Schreiber S, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. *Gastroenterology*. 425

2005;129:807-818.

60 Rutgeerts P, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. *Gastrointest Endosc*. 2006;63:433-442. 424

61 Lichtenstein GR, et al. Serious infection and mortality in patients with Crohn's disease: More than 5 years of follow-up in the TREAT (TM) registry. *Am J Gastroenterol*. 2012;107:1409-1422. 421

62 Louis E, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. *Gastroenterology*. 2012;142:63-70.e5. 416

63 Jorgensen KK, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. *Lancet*. 2017;10086:2304-2316. 413

64 Vermeire S, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. *Gut*. 2007;56:1226-1231. 413

65 Lichtenstein GR, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. *Gastroenterology*. 2005;128:862-869. 410

66 Regueiro M, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. *Gastroenterology*. 2009;136:441-450. 408

67 Vind I, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in copenhagen city and county, 2003-2005: A population-based study from the Danish crohn colitis database. *Am J Gastroenterol*. 2006;101:1274-1282. 402

68 Farrell RJ, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial. *Gastroenterology*. 2003;124:917-924. 402

69 Schnitzler F, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. *Gut*. 2009;58:492-500. 398

70 Vernier-Massouille G, et al. Natural history of pediatric Crohn's disease: A population-based cohort study. *Gastroenterology*. 2008;135:1106-1113. 395

71 Panes J, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. *Lancet*. 2016;388:1281-1290. 389

72 Baert F, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. *Gastroenterology*. 1999;116:22-28. 381

73 Karmiris K, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. *Gastroenterology*. 2009;137:1628-1640. 376

74 Rutgeerts P, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND trial. *Gastroenterology*. 2012;142:1102-1111.e2. 371

75 Sands BE, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. *Gastroenterology*. 2014;147:618-627.e3. 368

76 Gutierrez O, et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. *J Biol Chem*. 2002;277:41701-41705. 359

77 Ciccocioppo R, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. *Gut*. 2011;60:788-798. 358

78 Schoepfer AM, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. *Am J Gastroenterol*. 2010;105:162-169. 358

79 Van Assche G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. *Gastroenterology*. 2008;134:1861-1868. 358

80 Siegel CA, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease. *Clin Gastroenterol Hepatol*. 2009;7:874-881. 356

81 Esteve M, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. *Gut*. 2004;53:1363-1365. 355

82 Cheifetz A, et al. The incidence and management of infusion reactions to infliximab: A large center experience. *Am J Gastroenterol*. 2003;98:1315-1324. 354

83 Brooklyn TN, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. *Gut*. 351

2006;55:505-509.

84 Cleynen I, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. *Lancet*. 2016;387:156-167. 348

85 Lee JH, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. *Arthritis Rheum*. 2002;46:2565-2570. 346

86 Mittermaier C, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: A prospective 18-month follow-up study. *Psychosom Med*. 2004;66:79-84. 343

87 Colombel JF, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut*. 2017;66:839-851. 336

88 Nesbitt A, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor at agents. *Inflamm Bowel Dis*. 2007;13:1323-1332. 334

89 Sipponen T, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings. *Inflamm Bowel Dis*. 2008;14:40-46. 331

90 Hart AL, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. *Gastroenterology*. 2005;129:50-65. 331

91 Lewis JD, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. *Cell Host Microbe*. 2015;18:489-500. 325

92 Neurath MF, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. *Eur J Immunol*. 1997;27:1743-1750. 325

93 Burmester GR, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. *Ann Rheum Dis*. 2013;72:517-524. 320

94 Katz JA, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. *Am J Gastroenterol*. 2004;99:2385-2392. 319

95 Peyrin-Biroulet L, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. *Gastroenterology*. 2011;141:1621-1628.. 314

96 Rutgeerts P, et al. Optimizing anti-TNF treatment in inflammatory bowel disease. *Gastroenterology*. 2004;126:1593-1610. 313

97 Colombel JF, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. *Lancet*. 311

	2017;390:2779-2789.	
98	Ordas I, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms. *Clin Pharmacol Ther*. 2012;91:635-646.	310
99	Waetzig GH, et al. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. *J Immunol*. 2002;168:5342-5351.	310
100	Ma TY, et al. Mechanism of TNF-alpha modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. *Am J Physiol Gastrointest Liver Physiol*. 2005;288:422-430.	307

CD: Crohn disease; TC: Total citation.